Chronic myeloid leukaemia (CML) in remission represents a remarkable success story in modern cancer care. Thanks to targeted treatments, many people with CML can now achieve deep remission—where tests no longer detect signs of the disease. Some patients may even safely stop taking their daily medication while remaining in remission, living their lives free from treatment but under careful medical monitoring.
Understanding CML Remission
When doctors talk about remission in chronic myeloid leukaemia, they are describing a state where the disease is no longer detectable in the blood or bone marrow—the soft tissue inside bones where blood cells are made. This is different from many other types of cancer. In CML, remission doesn’t always mean the cancer is completely gone from the body, but rather that it has been reduced to such low levels that tests cannot find it.[1]
The most important type of remission for CML patients is called molecular remission. This occurs when the BCR-ABL1 gene—the abnormal gene that causes CML—cannot be found in blood or bone marrow samples. Achieving molecular remission is the goal of treatment because it indicates that the number of cancer cells has dropped to extremely low levels. When this deep molecular remission is sustained for at least two years, some patients may become eligible to discuss stopping their medication with their doctor.[6][13]
It is important to understand that CML in remission is still a chronic condition that requires lifelong monitoring. Even when no signs of disease appear, patients must have regular blood tests to ensure the leukaemia does not return. This careful watching allows doctors to catch any return of the disease early, when treatment can be restarted with excellent chances of success.[7]
The Path to Treatment-Free Remission
One of the most hopeful developments for people with CML is the concept of treatment-free remission. This means that some patients who have been taking medication for several years and have maintained deep molecular remission can safely stop their treatment. Not all patients are eligible for this approach, and those who do stop must continue to be monitored very closely.[4]
Clinical trials have shown that stopping treatment is safe for certain patients. To be considered for treatment-free remission, patients typically need to have been taking tyrosine kinase inhibitors (TKIs)—the main drugs used to treat CML—for around three to five years. Additionally, they must have been in deep molecular remission for at least two years. This means that during this period, very sensitive blood tests called PCR tests have not detected the BCR-ABL1 gene.[3][11]
Other criteria for stopping treatment include having CML that has never progressed to the more dangerous accelerated or blast phases, having no additional chromosome abnormalities beyond the Philadelphia chromosome (the main genetic change in CML), and being willing to have frequent blood tests. Patients must also understand what stopping treatment involves and work closely with their medical team throughout the process.[3]
When patients do stop their medication, they may experience some mild side effects. These can include aching muscles and joints or generally feeling unwell. Doctors call this withdrawal syndrome. These symptoms are usually mild and pass quickly. In rare cases where symptoms are more troublesome, patients may need to restart their medication.[3][11]
Monitoring After Stopping Treatment
Patients who stop taking their CML medication do not stop seeing their doctors. In fact, monitoring becomes more intensive after treatment stops. This careful watching is essential to catch any sign that the leukaemia is returning, which would mean restarting treatment immediately.[3]
The schedule for blood tests is very specific. During the first six months after stopping treatment, patients typically have a PCR blood test every month. This test looks for the BCR-ABL1 gene that drives CML. If the gene starts to reappear, it means the leukaemia is coming back. During the next six months, tests might be done every six to eight weeks. After the first year, if everything remains stable, testing may spread out to every two to three months.[3][11]
The reason for such frequent testing in the early months is that if CML does return, it most commonly happens within the first six months after stopping treatment. Most other patients who need to restart treatment do so within the first two years. After two years, the need to restart becomes less common, although it can still happen. This is why doctors continue to monitor patients for life, even if they remain in treatment-free remission for many years.[3][11]
Patients in treatment-free remission must also be monitored regularly for life and work closely with a haematologist (a doctor who specializes in blood diseases) or oncologist (a cancer specialist). Even after several years of successful treatment-free remission, regular check-ups remain necessary. The testing schedule may become less frequent over time, progressing from monthly to every other month, then every three months, and eventually to every six months, but monitoring never stops completely.[6][13]
What Happens If CML Returns
If blood tests start to detect the BCR-ABL1 gene again, it signals that CML is returning. This is not a medical emergency, and it does not mean treatment has failed. In fact, one of the strengths of treatment-free remission is that if the disease does come back, it can be caught very early through regular monitoring.[3]
When CML returns after stopping treatment, patients restart taking TKI medication. Usually, they go back on the same drug they were taking before the treatment break. However, if that drug caused troublesome side effects, a different TKI might be chosen instead. Once treatment restarts, doctors monitor blood tests every four weeks to watch for signs that the leukaemia is responding to treatment again.[3][11]
The good news is that the vast majority of people who restart treatment have a very good response. Studies over the last ten to fifteen years have shown that when medication is restarted early after detecting returning disease, the chance of achieving remission again is almost one hundred percent. This means that trying treatment-free remission does not harm a patient’s long-term outlook, as long as they remain committed to regular monitoring.[6][13]
Living With CML in Remission
Being in remission from CML, whether on or off treatment, represents a significant achievement. However, it also comes with its own challenges. Unlike some cancers where treatment ends and patients can move on with their lives, CML requires ongoing attention even when in remission.[7]
Many people with CML in remission look healthy and feel well. Others might not even know they have the condition. This can make it harder for patients to seek support or talk about their concerns. Some people feel they should just carry on as normal, especially if their doctor has said their disease is well controlled. However, living with chronic leukaemia can be emotionally difficult, even when the physical burden is low.[20]
Patients may experience anxiety about whether their treatment is working, worry about test results, or feel uncertain about the future. These feelings are completely normal and natural. It can help to talk to friends and family about these concerns, rather than keeping them inside. Medical teams understand these worries and can provide support or direct patients to additional help when needed.[20]
For those still taking daily medication, managing side effects becomes part of life. While TKIs are generally less harsh than traditional chemotherapy, they can still cause problems such as fatigue, muscle aches, swelling, nausea, or other symptoms. Learning to pace activities, getting regular gentle exercise, and staying hydrated can all help manage these effects.[21]
Many people find it helpful to connect with others who have CML, either through online communities or support groups. Talking with people who understand what living with chronic leukaemia is like can provide both practical advice and emotional comfort. Patient organizations and cancer support services can help connect people with these resources.[7]
The Outlook for CML in Remission
The outlook for people with chronic myeloid leukaemia has transformed dramatically over recent decades. In the 1970s, only twenty-two percent of people with CML survived five years after diagnosis. By 2017, this five-year survival rate had improved to seventy-one percent. With current treatments, many people with CML can expect to have a near-normal life expectancy.[1][4]
This remarkable change is due to the development of tyrosine kinase inhibitors, drugs that specifically target the abnormal protein produced by the BCR-ABL1 gene. These medications have turned CML from a potentially fatal disease into a manageable chronic condition for most patients. People diagnosed today have access to multiple different TKIs, each with different strengths and side effect profiles, allowing treatment to be tailored to individual needs.[2]
The concept of treatment-free remission represents the next step in improving outcomes for CML patients. It addresses not just survival, but quality of life. Being able to stop daily medication, while maintaining remission through careful monitoring, gives many patients back a sense of control and normality. It reduces the burden of side effects and the constant reminder of having cancer.[4]
Research continues to improve our understanding of who can safely stop treatment and for how long. Scientists are working to identify the mechanisms that allow some patients to maintain remission without medication, and how to make this possible for more people. Some researchers are even beginning to discuss the possibility of cure for certain CML patients who remain in treatment-free remission for many years.[4]
However, it remains important to be realistic. CML is still a chronic condition that requires lifelong monitoring. Not everyone will be able to stop treatment. Some people will need to restart medication after a period of treatment-free remission. For others, staying on medication long-term is the best option. What matters most is that each person works with their medical team to find the approach that works best for their individual situation.[7]
